Price (delayed)
$26.5
Market cap
$1.14B
P/E Ratio
10.95
Dividend/share
N/A
EPS
$2.42
Enterprise value
$1.04B
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform,
There are no recent dividends present for RGNX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.